Search research articles
Contact Us
Filters
Showing results (71-80 of 103) with videos related to
Page
of 11
Sort By:
International Journal of Cardiology
|
November 20, 2012
Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories
Dirk De Bacquer, Jean Dallongeville, Kornelia Kotseva, et al.
Atherosclerosis
|
April 10, 2022
Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?
Pavel Poredoš, Renata Cífková, Jeanette Anne Marie Maier, et al.
Atherosclerosis. Supplements
|
August 28, 2019
The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
Maciej Banach, Eric Bruckert, Olivier S Descamps, et al.
European Heart Journal
|
March 7, 2023
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, et al.
Pharmacological Research
|
February 19, 2021
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Maciej Banach, Peter E Penson, Michal Vrablik, et al.
Global Heart
|
November 17, 2025
The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!
Maciej Banach, Zlatko Fras, Dan Gaita, et al.
European Heart Journal. Acute Cardiovascular Care
|
October 6, 2025
A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients with Supraventricular Arrhythmia (Landi-UP)
Al-Medina Dizdarevic, Marek Šramko, Norman Mangner, et al.
European Heart Journal
|
October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek, Vera A Bittner, Philip Aylward, et al.
Journal of the American College of Cardiology
|
January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A Bittner, Michael Szarek, Philip E Aylward, et al.
Nutrition Reviews
|
September 24, 2017
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Arrigo F G Cicero, Alessandro Colletti, Gani Bajraktari, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 103) with videos related to
Sort By:
Page
of 11
International Journal of Cardiology
|
November 20, 2012
Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories
Dirk De Bacquer, Jean Dallongeville, Kornelia Kotseva, et al.
Atherosclerosis
|
April 10, 2022
Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?
Pavel Poredoš, Renata Cífková, Jeanette Anne Marie Maier, et al.
Atherosclerosis. Supplements
|
August 28, 2019
The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
Maciej Banach, Eric Bruckert, Olivier S Descamps, et al.
European Heart Journal
|
March 7, 2023
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, et al.
Pharmacological Research
|
February 19, 2021
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Maciej Banach, Peter E Penson, Michal Vrablik, et al.
Global Heart
|
November 17, 2025
The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!
Maciej Banach, Zlatko Fras, Dan Gaita, et al.
European Heart Journal. Acute Cardiovascular Care
|
October 6, 2025
A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients with Supraventricular Arrhythmia (Landi-UP)
Al-Medina Dizdarevic, Marek Šramko, Norman Mangner, et al.
European Heart Journal
|
October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek, Vera A Bittner, Philip Aylward, et al.
Journal of the American College of Cardiology
|
January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A Bittner, Michael Szarek, Philip E Aylward, et al.
Nutrition Reviews
|
September 24, 2017
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Arrigo F G Cicero, Alessandro Colletti, Gani Bajraktari, et al.
Page
of 11